Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy

Inclusion Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

- Maintenance therapy for opportunistic infections.

Patients must have:

- HIV infection.

- Kaposi's sarcoma that has relapsed or progressed.

- Mucocutaneous lesions (15 or more) and/or symptomatic mucosal lesions and/or visceral
Kaposi's sarcoma (symptomatic lymphedema qualifies patients in the absence of these
three conditions).

- NO active acute opportunistic infections requiring treatment with myelosuppressive
antibiotics (maintenance for OIs is permitted).

- Consent of parent or guardian if less than 18 years of age.

NOTE:

- This study is approved for prisoner participation.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

- Other active malignancies except basal cell carcinoma of the skin, or carcinoma in
situ of the cervix.

- Grade 3 or worse peripheral neuropathy.

- Altered mental status that would prevent informed consent or prevent study
compliance.

Patients with the following prior condition are excluded:

Neuropsychiatric history.

Prior Medication:

Excluded:

- Prior etoposide.

- Any other anti-KS drugs within 14 days prior to study entry.

- Any investigational drug other than antiretrovirals within 14 days prior to study
entry.

- Any prior investigational agent, if given as the ONLY prior treatment for KS.

Prior Treatment:

Excluded:

- Radiation therapy within 7 days prior to study entry.

Continued alcohol consumption or continued intravenous drug use that would impair ability
to comply with study requirements.